Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Common Equity (2022 - 2025)

TriSalus Life Sciences' Common Equity history spans 4 years, with the latest figure at -$33.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 30.77% year-over-year to -$33.9 million; the TTM value through Dec 2025 reached -$33.9 million, down 30.77%, while the annual FY2025 figure was -$33.9 million, 30.77% down from the prior year.
  • Common Equity reached -$33.9 million in Q4 2025 per TLSIW's latest filing, down from -$26.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $8.3 million in Q3 2023 to a low of -$198.4 million in Q2 2023.
  • Average Common Equity over 4 years is -$77.4 million, with a median of -$34.1 million recorded in 2025.
  • Peak YoY movement for Common Equity: soared 105.39% in 2023, then plummeted 346.43% in 2024.
  • A 4-year view of Common Equity shows it stood at -$177.1 million in 2022, then skyrocketed by 84.72% to -$27.1 million in 2023, then rose by 4.33% to -$25.9 million in 2024, then crashed by 30.77% to -$33.9 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Common Equity are -$33.9 million (Q4 2025), -$26.7 million (Q3 2025), and -$19.4 million (Q2 2025).